Bruker Daltonics Introduces Next Level of ClinProt Biomarker Discovery, Identification and Validation Solution at ASMS 2005

Bruker Daltonics Inc.

   --  New ClinProt Beads for Large Proteins, Glycomics and
        Antigen-Specific Analysis Combine with New Releases of
        Advanced Biomarker Analysis Software Tools

   Bruker Daltonics Inc. today announces the introduction of the next
level of its leading ClinProt(TM) solution for advanced biomarker
discovery, identification and validation in clinical proteomics.
   The extensive ClinProt portfolio of magnetic beads for sample
pre-fractionation has now been further expanded with novel
capabilities to address 1) biomarker analysis of large proteins, 2)
targeted glyco-protein analysis, and 3) antigen-specific enrichment of
selected biomarker molecules, combined with high-performance MALDI-TOF
read-out.
   New ClinProt 'Large-Protein Beads' are designed to overcome
previous limitations of biomarker discovery to peptide and small
proteins, and to exploit the full mass range of up to several 100
kDaltons supported by Bruker Daltonics' cutting-edge MALDI-TOF mass
spectrometers. These novel Large-Protein Beads are complemented by a
new DHAP matrix product, which is optimized for high molecular weight
proteins.
   In addition, new ClinProt 'Glyco-Beads' bridge the gap between
clinical proteomics and the important field of glycomics. The unique
Glyco-Beads offer multiple methods for glyco-protein enrichment,
including both chemical capture or lectin-capture strategies. After
glyco-protein enrichment, the ClinProt solution now offers multiple
glycomics workflows: for example, profiling of all glycosylated
peptides or proteins, or of selected glycan-structures can be very
informative in cancer research, as many cancer cells show altered
glycans on their surface. In-depth structural analysis and
identification of specific glyco-proteins can then be accomplished
using the Company's well-established Proteineer(TM) solution for
expression proteomics, involving MALDI-TOF/TOF and/or LC-ESI-MS/MS
workflows.
   Finally, novel ClinProt 'Antibody-Capture Beads' allow the
specific enrichment of different protein groups with the same antigen
specificity or even of specific proteins, thus giving access to
low-abundance proteins in plasma. Enriching specific proteins via
coupling of customer-selected antibodies can give the specificity of
an immunoassay, combined with the confidence of a mass spectrometry
read-out. This allows scientists to see all proteins bound to an
antibody at once, and to distinguish the specific protein from other
isoforms, or from undesired cross-contamination, thereby considerably
increasing the confidence in any antibody-based assay.
   The new ClinProt bead products are complemented by the new,
advanced ClinProTools(TM) 2.0 bioinformatics package for streamlined
data interpretation. ClinProTools 2.0 combines intuitive data
visualization with sophisticated pattern recognition algorithms for
the determination of predictive biomarker panels. Spectra not reaching
the desired quality standard can be excluded from the analysis in the
graphical user interface. The new proprietary QuickClassifier(TM)
algorithm circumvents the common problem of model generation being
extremely time-consuming. The QuickClassifier provides a
classification result in a few seconds, even for large data sets. This
is further complemented by a new multi-class Support Vector Machine
(mSVM) for high-end classifications. Multiple sample classes, for
example originating from different control groups or from staging of a
disease, are supported by the algorithms and likewise by the
visualization tools. A correlation matrix gives an overview of all
positively or negatively correlated peaks, even if they have not been
selected for a predictive pattern. This gives an optimal overview of
co-expressed signals in a set of profiling samples.
   In addition, newly introduced ProfileAnalysis(TM) 1.0 software
further expands the use of electrospray ionization (ESI)
time-of-flight (TOF) mass spectrometry for clinical research and
pharmaceutical development applications, using Bruker Daltonics'
micrOTOF(TM) ESI-TOF systems. ProfileAnalysis software is well-suited
for small molecule profiling of complex biological fluids, e.g. urine.
The pattern recognition process is supported by principle component
analysis, and optimized visualization tools support the researcher
during the application of these sophisticated mathematical approaches.
   Professor Dr. Thiery, Head of the Institute for Clinical Chemistry
and Laboratory Medicine in Leipzig, Germany, commented on the new
ClinProt products: "In our laboratory, the ClinProt system has
recently been shown to overcome reproducibility problems which were
reported for chip-based pre-fractionation techniques. MALDI-TOF mass
spectrometry-based profile analysis in our hands has proved to be a
promising tool for future routine applications in the clinical
laboratory. Our recently published standard operating procedures
(Baumann et al., Clinical Chemistry 2005; 51: 973-980) for
standardized sample preparation give every researcher access to proven
pre-fractionation techniques when starting research in clinical
proteomics."
   Frank Laukien, Ph.D., President and CEO of Bruker Daltonics,
stated: "The introduction of our next level of ClinProt sample
preparation beads and analysis software drives biomarker analysis one
step further, as it gives access to novel applications and important
assays that previously could not be addressed efficiently. Moreover,
our next-generation ClinProt and Proteineer solutions now also are
applicable to new fields like glyco-biology, which is expected to have
significant impact in cancer research."
   The next-level tools in our ClinProt solution will be presented in
scientific contributions from Bruker Daltonics during the 53rd ASMS
conference on Mass Spectrometry in San Antonio, Texas this week.

   ABOUT BRUKER BIOSCIENCES (NASDAQ: BRKR)

   Bruker BioSciences Corporation, headquartered in Billerica,
Massachusetts, is the publicly traded parent company of Bruker
Daltonics Inc. and Bruker AXS Inc. Bruker AXS is a leading developer
and provider of life science and advanced materials research tools
based on x-ray technology. Bruker Daltonics is a leading developer and
provider of innovative life science tools based on mass spectrometry.
Bruker Daltonics also offers a broad line of nuclear, biological and
chemical (NBC) detection systems for homeland security. For more
information: www.bruker-biosciences.com

   CAUTIONARY STATEMENT

   Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements as
that term is defined in the Private Securities Litigation Reform Act
of 1995. Any forward-looking statements contained herein are based on
current expectations, but are subject to a number of risks and
uncertainties. The factors that could cause actual future results to
differ materially from current expectations include, but are not
limited to, risks and uncertainties relating to the Company's
reorganization strategies, integration risks, failure of conditions,
technological approaches, product development, market acceptance, cost
and pricing of the Company's products, changes in governmental
regulations, capital spending and government funding policies, FDA and
other regulatory approvals to the extent applicable, competition, the
intellectual property of others, patent protection and litigation.
These and other factors are identified and described in more detail in
our filings with the SEC, including, without limitation, our annual
report on Form 10-K for the year ended December 31, 2004, our most
recent quarterly reports on Form 10-Q and our current reports on Form
8-K. We disclaim any intent or obligation to update these
forward-looking statements.